Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cara Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cara Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Licensing Agreements 12
Vifor-Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with Cara Therapeutics 12
Cara Therapeutics Enters Into Licensing Agreement With Maruishi Pharma For CR845 14
Cara Therapeutics Enters Into Licensing Agreement With Chong Kun Dang Pharma For CR845 16
Equity Offering 17
Cara Therapeutics Raises USD98.3 Million in Public Offering of Shares 17
Cara Therapeutics Raises USD92 Million in Public Offering of Shares 19
Cara Therapeutics Raises USD80.5 Million in Public Offering of Shares 21
Cara Therapeutics Raises USD0.1 Million in Private Placement of Shares 23
Cara Therapeutics Completes IPO For US$63.3 Million 24
Cara Therapeutics Inc – Key Competitors 26
Cara Therapeutics Inc – Key Employees 27
Cara Therapeutics Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Aug 07, 2018: Cara Therapeutics Reports Second Quarter 2018 Financial Results 29
May 09, 2018: Cara Therapeutics Reports First Quarter 2018 Financial Results 31
Mar 15, 2018: Cara Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results 33
Nov 02, 2017: Cara Therapeutics Reports Third Quarter 2017 Financial Results 36
Aug 03, 2017: Cara Therapeutics Reports Second Quarter 2017 Financial Results 38
May 04, 2017: Cara Therapeutics Reports First Quarter 2017 Financial Results 40
Mar 09, 2017: Cara Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results 42
Product News 44
10/17/2017: Cara Therapeutics Announces Participation in ANESTHESIOLOGY 2017 44
08/01/2017: Cara Therapeutics Appoints Mani Mohindru, Ph.D., Chief Financial Officer 45
06/27/2018: Cara Therapeutics Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845 in Patients Undergoing Abdominal Surgery 46
06/23/2017: Cara Receives Breakthrough Therapy Designation from FDA for I.V. CR845 for the Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients 47
05/17/2017: Cara Therapeutics to Present at the 17th Annual Conference on Pain Therapeutics 48
05/14/2018: Cara Therapeutics to Present at the International Investigative Dermatology 2018 Meeting 49
05/12/2017: Cara Therapeutics to Host KOL Meeting on Chronic Kidney Disease-Associated Pruritus 50
04/10/2018: Cara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney Foundation 51
03/28/2017: Cara Therapeutics Announces Positive Top-Line Data From Part A of Phase 2/3 Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus 52
Clinical Trials 54
Jul 19, 2018: Enteris BioPharmas Feasibility-to-Licensing Partner, Cara Therapeutics, Doses First Patient in Phase 2 Trial of Peptelligence-Engineered Oral KORSUVA 54
Jul 11, 2018: Cara Therapeutics Announces Dosing of Patients in Phase 2 Trial of Oral KORSUVA (CR845/difelikefalin) for Pruritus in Stage III-V Chronic Kidney Disease (CKD) Patients 55
Feb 28, 2018: Cara Therapeutics Doses First Patient in Phase 1 Trial of Oral KORSUVA (CR845/difelikefalin) in Chronic Liver Disease Patients 56
Jan 31, 2018: Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus 57
Oct 31, 2017: Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting 58
Oct 31, 2017: Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Doses First Patient in Phase 1 Study of Peptelligence-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients 59
Oct 25, 2017: Cara Therapeutics Doses First Patient in Phase 1 Study of Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients 60
Oct 16, 2017: Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus 61
Oct 16, 2017: Cara Therapeutics to Present Data at Kidney Week 2017 62
Oct 04, 2017: Cara Therapeutics to Present at the Janney Montgomery Scott Osteoarthritis Pain Conference 63
Aug 31, 2017: Cara Therapeutics to Participate in September Medical Meetings 64
Jul 12, 2017: Cara Therapeutics Announces Summary Data From Phase 1 Trial of Oral CR845 in Hemodialysis Patients with Chronic Kidney Disease 65
Jun 29, 2017: Cara Therapeutics Announces Top-line Results From Phase 2b Trial of Oral CR845 in Chronic Pain Patients With Osteoarthritis of the Hip or Knee 66
Jun 21, 2017: Cara Therapeutics Reports Continuation of Phase 3 Trial of I.V. CR845 in Postoperative Pain Following Interim Assessment 67
Apr 24, 2017: Cara Therapeutics Announces Positive Data From Quantitative Phase 1 Trial Measuring Respiratory Safety of I.V. CR845 68
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cara Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cara Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cara Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Vifor-Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with Cara Therapeutics 12
Cara Therapeutics Enters Into Licensing Agreement With Maruishi Pharma For CR845 14
Cara Therapeutics Enters Into Licensing Agreement With Chong Kun Dang Pharma For CR845 16
Cara Therapeutics Raises USD98.3 Million in Public Offering of Shares 17
Cara Therapeutics Raises USD92 Million in Public Offering of Shares 19
Cara Therapeutics Raises USD80.5 Million in Public Offering of Shares 21
Cara Therapeutics Raises USD0.1 Million in Private Placement of Shares 23
Cara Therapeutics Completes IPO For US$63.3 Million 24
Cara Therapeutics Inc, Key Competitors 26
Cara Therapeutics Inc, Key Employees 27
List of Figures
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cara Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cara Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10